Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: Sustained improvement in cognition and quality of life.
Braun B, Fischbach F, Richter J, Pfeffer LK, Fay H, Reinhardt S, Friese MA, Stellmann JP, Kröger NM, Heesen C, Häußler V. Braun B, et al. Among authors: kroger nm. Mult Scler Relat Disord. 2024 Feb;82:105414. doi: 10.1016/j.msard.2023.105414. Epub 2023 Dec 27. Mult Scler Relat Disord. 2024. PMID: 38176284 Free article.
Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation.
Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, Massoud R, Rathje K, Richter J, Schäfersküpper M, Niederwieser C, Kunte A, Heidenreich S, Ayuk F, Kröger N. Oechsler S, et al. Bone Marrow Transplant. 2024 Apr;59(4):550-557. doi: 10.1038/s41409-024-02220-7. Epub 2024 Feb 6. Bone Marrow Transplant. 2024. PMID: 38321269 Free PMC article.
Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation.
Steiner N, Massoud R, Klyuchnikov E, Gagelmann N, Richter J, Niederwieser C, Rathje K, Urbanowicz T, Kunte A, Engelmann J, Ihne C, Lastovytska I, Lindhauer C, Marquard F, Reichard M, Ryzhkova A, Sabauri R, Schäfersküpper M, Seyedi N, Kalogeropoulos G, Heidenreich S, Rudolph I, Zeck G, Janson D, Wolschke C, Ayuk F, Kröger N. Steiner N, et al. Bone Marrow Transplant. 2024 Sep;59(9):1265-1274. doi: 10.1038/s41409-024-02328-w. Epub 2024 Jun 14. Bone Marrow Transplant. 2024. PMID: 38877098 Free PMC article.
Comparable Results Between 8 and 12 Gray TBI in Combination With Fludarabine and Post-Transplant Cyclophosphamide in MRD-Negative but Not in MRD-Positive Acute Lymphoblastic Leukemia Patients Transplanted in First Complete Remission.
Steiner N, Massoud R, Richter J, Perekhrestenko T, Gagelmann N, Niederwieser C, Rathje K, Lastovytska I, Schäfersküpper M, Heidenreich S, Rudolph I, Zeck G, Janson D, Wolschke C, Ayuk FA, Klyuchnikov E, Kröger N. Steiner N, et al. Eur J Haematol. 2025 Jan;114(1):79-88. doi: 10.1111/ejh.14305. Epub 2024 Sep 19. Eur J Haematol. 2025. PMID: 39300830 Free PMC article.
Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis.
Rathje K, Gagelmann N, Badbaran A, Langebrake C, Dadkhah A, Richter J, Massoud R, Schäfersküpper M, Marquard FE, Oechsler S, Klyuchnikov E, Rudolph I, Heidenreich S, Niederwieser C, Lueck C, Janson D, Wolschke C, Fehse B, Ayuk F, Kröger N. Rathje K, et al. Am J Hematol. 2025 Feb;100(2):200-209. doi: 10.1002/ajh.27529. Epub 2024 Nov 16. Am J Hematol. 2025. PMID: 39548811 Free PMC article.
Clearance of Driver Mutations after Transplantation for Myelofibrosis.
Gagelmann N, Quarder M, Badbaran A, Rathje K, Janson D, Lück C, Richter J, Marquard F, Oechsler S, Massoud R, Klyuchnikov E, Rudolph I, Schäfersküpper M, Niederwieser C, Heidenreich S, Berger C, Fehse B, Wolschke C, Ayuk F, Kröger N. Gagelmann N, et al. N Engl J Med. 2025 Jan 9;392(2):150-160. doi: 10.1056/NEJMoa2408941. N Engl J Med. 2025. PMID: 39778169
Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI; Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group. Kröger N, et al. Br J Haematol. 2005 Jun;129(5):631-43. doi: 10.1111/j.1365-2141.2005.05513.x. Br J Haematol. 2005. PMID: 15916686 Free article.
Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N, Badbaran A, Zabelina T, Ayuk F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander AR. Kröger N, et al. Biol Blood Marrow Transplant. 2013 Mar;19(3):398-404. doi: 10.1016/j.bbmt.2012.10.008. Epub 2012 Oct 16. Biol Blood Marrow Transplant. 2013. PMID: 23078786 Free article.
568 results